Filed with ASX · · 3 pages · English
This approval allows the investigator-sponsored trial led by Vanderbilt Health to commence, marking a significant regulatory milestone for the company. The trial aims to address the significant unmet medical need in AML, which remains a challenging disease despite advances in treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement FDA CLEARANCE FOR VANDERBILT HEALTH INVESTIGATOR SPONSORED TRIAL FOR ACUTE MYELOID LEUKAEMIA • US FDA has provided approval for Vanderbilt Health to commence the investigator-sponsored clinical trial (IST) evaluating HMBD-002 in combination with venetoclax and azacitidine in...
Percheron Therapeutics Limited on 6ix
